Current Research Studies
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Nebulized Bacteriophage Treatment in Outpatient Adult Cystic Fibrosis (CF) Subjects with Chronic Pseudomonas aeruginosa (PsA) Pulmonary Infection
BiomX Phase 2b Nebulized Bacteriophage in CF
What is the goal of the study?
People with cystic fibrosis (CF) often have lung infections caused by the bacteria, Pseudomonas aeruginosa (PsA), which require treatment with antibiotics. This is a Phase 2b study which aims to evaluate the efficacy of a nebulized bacteriophage, BX004, on sputum PsA burden in adults with CF with chronic PsA pulmonary infection after 8 weeks of treatment.
Who can participate in the study?
Confirmed diagnosis of cystic fibrosis Age 18 years and older Able to cough up sputum History of Pseudomonas aeruginosa lung infection Pseudomonas aeruginosa moderate to large amount in sputum at screening